Gambaran Umum
Shin Nippon Biomedical Laboratories, Ltd., based in Japan, operates primarily in the pharmaceuticals and healthcare industry, focusing extensively on preclinical and clinical drug development services. The company offers a comprehensive portfolio of services, including toxicology studies, pharmacokinetics, and drug metabolism studies crucial for regulatory submissions. Key projects often involve collaborative research and development partnerships aimed at advancing innovative therapeutic products. The company supports global pharmaceutical and biotechnology firms in navigating the complexities of drug development, from discovery through to regulatory approval. Shin Nippon Biomedical Laboratories leverages advanced technology and extensive expertise to enhance the efficacy and safety evaluation of new therapeutics, positioning itself as a critical player in the biomedical research field.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Shin Nippon Biomedical Laboratories, Ltd. per 2025 Jun 30 adalah 33,341.96 MM.
- Nilai operating income untuk Shin Nippon Biomedical Laboratories, Ltd. per 2025 Jun 30 adalah 2,789.48 MM.
- Nilai net income untuk Shin Nippon Biomedical Laboratories, Ltd. per 2025 Jun 30 adalah 5,063.08 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 33,341.96 | 2,789.48 | 5,063.08 |
2025-03-31 | 32,413.00 | 2,985.00 | 4,924.00 |
2024-12-31 | 30,701.11 | 3,520.59 | 4,942.16 |
2024-09-30 | 27,074.00 | 1,892.00 | 3,896.00 |
2024-06-30 | 26,195.02 | 2,790.09 | 4,280.14 |
2024-03-31 | 26,450.47 | 4,162.37 | 5,531.26 |
2023-12-31 | 26,703.00 | 3,997.00 | 5,503.00 |
2023-09-30 | 26,626.00 | 5,282.00 | 4,607.00 |
2023-06-30 | 26,848.00 | 5,758.00 | 5,489.00 |
2023-03-31 | 25,090.00 | 5,245.00 | 6,060.00 |
2022-12-31 | 21,173.00 | 4,679.00 | 6,231.00 |
2022-09-30 | 20,135.00 | 4,540.00 | 8,043.00 |
2022-06-30 | 18,753.00 | 4,418.00 | 7,245.00 |
2022-03-31 | 17,748.00 | 4,196.00 | 7,127.00 |
2021-12-31 | 17,636.00 | 4,204.00 | 7,432.00 |
2021-09-30 | 16,068.00 | 3,337.00 | 6,025.00 |
2021-06-30 | 14,978.00 | 2,573.00 | 4,844.00 |
2021-03-31 | 15,110.00 | 2,529.00 | 3,661.00 |
2020-12-31 | 14,910.00 | 2,278.00 | 2,421.00 |
2020-09-30 | 15,175.00 | 2,311.00 | 2,812.00 |
2020-06-30 | |||
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | 118.71 | 118.71 |
2024-09-30 | 93.58 | 93.58 |
2024-06-30 | 102.81 | 102.81 |
2024-03-31 | 132.86 | |
2023-12-31 | 132.19 | 132.19 |
2023-09-30 | 110.66 | 110.66 |
2023-06-30 | 131.85 | 131.85 |
2023-03-31 | 145.56 | |
2022-12-31 | 149.67 | 149.67 |
2022-09-30 | 193.20 | 193.20 |
2022-06-30 | 174.02 | 174.02 |
2022-03-31 | 171.19 | |
2021-12-31 | 178.52 | 178.52 |
2021-09-30 | 144.72 | 144.72 |
2021-06-30 | 116.35 | 116.35 |
2021-03-31 | 87.94 | |
2020-12-31 | 58.15 | 58.15 |
2020-09-30 | 67.54 | 67.54 |
2020-06-30 | 77.68 | 77.68 |
2020-03-31 | 61.25 |
Arus Kas: Operasi, Investasi, Pendanaan
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | |||
2025-03-31 | 7,035.00 | -11,691.00 | 5,914.00 |
2024-12-31 | |||
2024-09-30 | 1,650.00 | -10,758.00 | 10,852.00 |
2024-06-30 | |||
2024-03-31 | 2,106.73 | -6,907.73 | 5,318.66 |
2023-12-31 | |||
2023-09-30 | 1,899.00 | -7,022.00 | 2,120.00 |
2023-06-30 | |||
2023-03-31 | 4,004.00 | -5,930.00 | 6,266.00 |
2022-12-31 | |||
2022-09-30 | 7,170.00 | -7,227.00 | 4,280.00 |
2022-06-30 | |||
2022-03-31 | 5,952.00 | -4,268.00 | -4,911.00 |
2021-12-31 | |||
2021-09-30 | 5,301.00 | 444.00 | -4,915.00 |
2021-06-30 | |||
2021-03-31 | 4,746.00 | -268.00 | -2,471.00 |
2020-12-31 | |||
2020-09-30 | 2,706.00 | -1,277.00 | -613.00 |
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Efektivitas Manajemen
- roa untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.06.
- roe untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.15.
- roic untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.07.
- croic untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.02.
- ocroic untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.10.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | 0.06 | 0.15 | 0.07 | 0.02 | 0.10 |
2025-03-31 | 0.06 | 0.14 | 0.06 | 0.02 | 0.02 |
2024-12-31 | 0.05 | 0.13 | 0.05 | 0.03 | 0.02 |
2024-09-30 | 0.06 | 0.13 | 0.06 | 0.02 | 0.03 |
2024-06-30 | 0.21 | ||||
2024-03-31 | 0.19 | ||||
2023-12-31 | 0.14 | -0.08 | |||
2023-09-30 | 0.20 | 0.17 | |||
2023-06-30 | 0.26 | ||||
2023-03-31 | 0.31 | ||||
2022-12-31 | |||||
2022-09-30 | 0.00 | ||||
2022-06-30 | 0.00 | 0.00 | |||
2022-03-31 | 0.00 | ||||
2021-12-31 | 0.00 | ||||
2021-09-30 | 0.17 | 0.41 | |||
2021-06-30 | 0.12 | 0.16 | 0.07 | 0.16 | |
2021-03-31 | 0.09 | 0.22 | 0.13 | 0.07 | 0.17 |
2020-12-31 | 0.06 | 0.14 | 0.08 | 0.03 | 0.09 |
2020-09-30 | 0.06 | 0.13 | 0.10 | 0.03 | 0.09 |
2020-06-30 | 0.07 | 0.13 | 0.09 | 0.00 | 0.09 |
2020-03-31 | 0.05 | 0.09 | 0.08 | 0.00 | 0.10 |
Gross Margins
- marjin kotor untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.45.
- marjin bersih untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.15.
- marjin operasi untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.09.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.45 | 0.15 | 0.09 |
2025-03-31 | 0.49 | 0.16 | 0.11 |
2024-12-31 | 0.48 | 0.14 | 0.07 |
2024-09-30 | 0.49 | 0.16 | 0.11 |
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | 0.20 | 0.21 | |
2023-06-30 | 0.20 | 0.21 | |
2023-03-31 | 0.24 | 0.21 | |
2022-12-31 | |||
2022-09-30 | 0.00 | 0.00 | |
2022-06-30 | 0.00 | 0.00 | |
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | 0.50 | 0.32 | 0.17 |
2021-03-31 | 0.46 | 0.24 | 0.17 |
2020-12-31 | 0.50 | 0.16 | 0.15 |
2020-09-30 | 0.50 | 0.19 | 0.15 |
2020-06-30 | 0.51 | 0.22 | 0.16 |
2020-03-31 | 0.52 | 0.18 | 0.15 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) |